Date published: 2026-6-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

Sorafenib (CAS 284461-73-0)

5.0(3)
Write a reviewAsk a question

See product citations (129)

Alternate Names:
Sorafenib is also known as Sorafenibum.
Application:
Sorafenib is an inhibitor of Raf-1 and B-RAF as well as several tyrosine kinases. Sorafenib also inhibits tumor angiogenesis by inducing tumor cell apoptosis.
CAS Number:
284461-73-0
Purity:
≥98%
Molecular Weight:
464.82
Molecular Formula:
C21H16ClF3N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Sorafenib is a RAF kinase inhibitor which suppresses ERK phosphorylation. Studies indicate that Sorafenib induces c-Raf phosphorylation at both Ser-43 and Ser-259. When combined with vitamin K1, phosphorylation is increased at these serine residues. Sorafenib also induces the phosphorylation of PKA. In addition, Sorafenib induces c-Met phosphorylation at Tyr-1349, which consequently induces PI3K-Akt phosphorylation. Studies determined that Sorafenib inhibits other kinases such as Flk-1 (VEGFR2), PDGFR (platelet-derived growth factor receptor), Flt-3/Flk-2 (FLT3), Ret, and c-Kit. Sorafenib is an inhibitor of Raf-1, Raf-B, PDGFR-betaand Flt-4. Its ability to affect the Raf/Mek/Erk pathway makes it useful in cancer research studies. Sorafenib is also known as Sorafenibum, BAY 43-9006, and 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide.


Sorafenib (CAS 284461-73-0) References

  1. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.  |  Richly, H., et al. 2003. Int J Clin Pharmacol Ther. 41: 620-1. PMID: 14692720
  2. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.  |  Khire, UR., et al. 2004. Bioorg Med Chem Lett. 14: 783-6. PMID: 14741289
  3. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  |  Wilhelm, SM., et al. 2004. Cancer Res. 64: 7099-109. PMID: 15466206
  4. Sorafenib.  |  Rini, BI. 2006. Expert Opin Pharmacother. 7: 453-61. PMID: 16503817
  5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.  |  Liu, L., et al. 2006. Cancer Res. 66: 11851-8. PMID: 17178882
  6. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.  |  Carr, BI., et al. 2011. Cancer Biol Ther. 12: 531-8. PMID: 21734462
  7. A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.  |  Di Cesare Mannelli, L., et al. 2015. Neurotoxicology. 50: 101-7. PMID: 26254739
  8. Sorafenib for Advanced and Refractory Desmoid Tumors.  |  Gounder, MM., et al. 2018. N Engl J Med. 379: 2417-2428. PMID: 30575484
  9. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.  |  Xia, S., et al. 2020. EBioMedicine. 51: 102610. PMID: 31918403
  10. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.  |  Tang, W., et al. 2020. Signal Transduct Target Ther. 5: 87. PMID: 32532960
  11. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.  |  Kong, FH., et al. 2021. Theranostics. 11: 5464-5490. PMID: 33859758
  12. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.  |  Li, D., et al. 2022. J Exp Clin Cancer Res. 41: 116. PMID: 35354475
  13. Retraction Note: Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.  |  Liu, C., et al. 2022. BMC Gastroenterol. 22: 421. PMID: 36109709
  14. Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.  |  Kurma, K., et al. 2022. Int J Mol Sci. 23: PMID: 36555845

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Sorafenib, 5 mg

sc-220125
5 mg
$57.00

Sorafenib, 50 mg

sc-220125A
50 mg
$100.00

Sorafenib, 500 mg

sc-220125B
500 mg
$250.00